BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
PARTNERSHIPS

Business Development Opportunities

Working together to improve the lives of patients living with serious and debilitating chronic conditions.

BDSI actively seeks partnerships and product licenses in the areas of neurology, pain, psychiatry, and select rare diseases. We collaborate in ways that expand and strengthen the process of commercializing innovative therapies, and are open to working within a variety of mutually beneficial deal structures.

Working With BDSI

For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander.

Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050

Asterisks denote required fields

Recent BDSI News

September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
September 3, 2021

RALEIGH, N.C. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
September 28, 2021BDSI $3.66/ - -2.14%
Data provided by Nasdaq. Minimum 15 minutes delayed.